title: Is thrombin time too sensitive to dabigatran anticoagulation for clinical decision making in the setting of acute hemorrhage?
authors.affiliation: Pathology and Laboratory Medicine Service, VA Connecticut Healthcare System, West Haven, CT, USA, alexa.siddon@yale.edu.
authors.forename: Alexa J
authors.initials: AJ
authors.lastname: Siddon
authors.forename: Henry M
authors.initials: HM
authors.lastname: Rinder
authors.forename: Jeanne E
authors.initials: JE
authors.lastname: Hendrickson
authors.forename: Christopher A
authors.initials: CA
authors.lastname: Tormey
mesh_terms: D000208:Acute Disease; D000368:Aged; D001562:Benzimidazoles / Q000627:therapeutic use*; D000069604:Dabigatran; D003657:Decision Making; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D020300:Intracranial Hemorrhages / Q000175:diagnosis* / Q000188:drug therapy*; D008297:Male; D013918:Thrombin Time / Q000379:methods; D015091:beta-Alanine / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D001562:Benzimidazoles; D005343:Fibrinolytic Agents; D015091:beta-Alanine; D000069604:Dabigatran